CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL) recall — Chiesi Usa, Inc. (Class II)
Chiesi Usa, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL) — a Class II recall, initiated 2026-07-06 and posted to the FDA enforcement report on 2026-07-22, under recall number D-0689-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Lack of Assurance of Sterility”. From the product description, the form is injectable emulsion, the strengths given are 50 mg/100 mL and 0.5 mg/mL and it is marked Rx only. 1 National Drug Code number is printed in the record: 10122-611-10. Distribution is recorded as “Nationwide within the United States” — Nationwide (US), with the recalling firm on record in NC, United States. It is the only recall number the FDA has filed under event ID 99376. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0689-2026 |
|---|---|
| FDA event ID | 99376 |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | Chiesi Usa, Inc. |
| Recall initiated | 2026-07-06 |
| Reported by FDA | 2026-07-22 |
| Report lag | 16 days from initiation to report |
| Distribution | Nationwide within the United States — Nationwide (US) |
| Firm location on record | NC, United States |
| Product description (source) | CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL), 10 Single Use Vials, Rx Only, Manufactured for: Chiesi USA, Inc., Cary, NC 27518, by Fresenius Kabi, Graz, Austria, NDC 10122-611-10. |
Reason reported by FDA
Lack of Assurance of Sterility
5 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
6 identifying values matched by exact pattern in the 30-word product description above; each is a literal substring of it.
| Product named | CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL) |
|---|---|
| Form | Injectable Emulsion |
| Strength | 50 mg/100 mL · 0.5 mg/mL |
| NDC | 10122-611-10 |
| Marketing category | Rx only |
| Manufactured for | Chiesi USA, Inc. |
Reported in the same month (2026-07)
111 enforcement reports carry a report date in 2026-07; these 8 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Nystatin Cream USP, 15 g | D-0677-2026 | Padagis US LLC | Class II | 2026-07-22 |
| CVS Health, 6.5% | D-0678-2026 | Bell Pharmaceuticals, Inc | Class II | 2026-07-22 |
| Clinere, 0.50 mL | D-0679-2026 | Bell Pharmaceuticals, Inc | Class II | 2026-07-22 |
| QC Quality Choice, 6.5% | D-0680-2026 | Bell Pharmaceuticals, Inc | Class II | 2026-07-22 |
| TopCare Health, 6.5% | D-0681-2026 | Bell Pharmaceuticals, Inc | Class II | 2026-07-22 |
| AUDIOLOGIST'S CHOICE, 6.5% | D-0682-2026 | Bell Pharmaceuticals, Inc | Class II | 2026-07-22 |
| FAMILY Wellness, 6.5% | D-0683-2026 | Bell Pharmaceuticals, Inc | Class II | 2026-07-22 |
| GOOD NEIGHBOR PHARMACY, 6.5% | D-0684-2026 | Bell Pharmaceuticals, Inc | Class II | 2026-07-22 |
Nearest Class II recalls by date
213 of 250 indexed records share the Class II tier; the 8 nearest to 2026-07-22 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| LEADER, 6.5% | D-0685-2026 | Bell Pharmaceuticals, Inc | 6.5% · Drops | 2026-07-22 |
| Foster & Thrive, 6.5% | D-0686-2026 | Bell Pharmaceuticals, Inc | 6.5% | 2026-07-22 |
| meijer, 6.5% | D-0687-2026 | Bell Pharmaceuticals, Inc | 6.5% | 2026-07-22 |
| CAREone, 6.5% | D-0688-2026 | Bell Pharmaceuticals, Inc | 6.5% | 2026-07-22 |
| BD ChloraPrep Clear, 2% | D-0690-2026 | Carefusion 213, LLC | 2% · Solution | 2026-07-22 |
| Methohexital Sodium for Injection, 500 mg | D-0662-2026 | Onesource Specialty Pharma Ltd | 500 mg · for Injection | 2026-07-15 |
| Medline Remedy Specialized Silicone Cream (Hydraguard-D ), 59 mL | D-0663-2026 | Biomed Laboratories, Llc. | 59 mL · Cream | 2026-07-15 |
| Methohexital Sodium, 100 mg/10 mL | D-0664-2026 | Quva Pharma, Inc. | 100 mg/10 mL | 2026-07-15 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 10122-611-10 at the FDA source to confirm it is covered.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Chiesi Usa, Inc. (1 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0689-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0689-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-07-22
- Ingested
- 2026-08-22
- Record hash
9849a7710d08399d
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.